cyrilzakka/clinical-trials huggingface dataset:
Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

The purpose of this study is to find out what kinds of information people would like to receive from a new kind of genetic testing, and how they respond to this new kind of testing.


Eligibility Criteria:
Inclusion Criteria:

* Male or Female age 18 or older
* Personal history of breast cancer AND one of the following:
* Invasive breast cancer or DCIS diagnosed at or before age 45 Invasive breast cancer diagnosed at/before age 50 with one or more of the following:
* Limited family history (Fewer than 2 first- or second-degree female relatives in the same lineage that lived to age 45. The "limited family history" can occur on either the maternal or paternal side of the family.)
* 1 or more first-/second-degree relatives with invasive BC at/before 50
* 1 or more first-/second-degree relatives with invasive epithelial ovarian cancer (any age)
* 1 or more first- or second-degree relatives with male breast cancer
* 2 or more first- or second-degree relatives with pancreas cancer
* Invasive breast cancer diagnosed at or before age 60 with at least 2 first or second-degree relatives affected with any combination of invasive breast cancer before age 50, invasive epithelial ovarian cancer at any age, male breast cancer, or pancreas cancer.
* Full sequence BRCA1 and BRCA2 testing completed with no deleterious mutation identified.

Exclusion Criteria:

* Unable to provide informed consent for testing
* Unable to complete English language questionnaire
Single Ascending Dose Study (SAD) iv Formulation

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* BIM 19-30 kg/m2

Exclusion Criteria:

* Potassium outside normal reference values
* ECG findings outside normal range
The Status of Parathyroid Hormone Secretion in Covid-19 Patients

COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs. This cytokine-mediated widespread inflammation can also affect the parathyroid glands, resulting in impaired parathyroid secretion.

Researchers evaluated the levels of parathyroid hormone, calcium, phosphorus, and alkaline phosphatase in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known parathyroid disease.

The researchers examined the association of parathyroid hormone secretion with COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone level of healthy people without COVID-19 infection and known parathyroid disease with the parathyroid hormone level of Covid-19 patients.

The coronavirus-2 (SARS-COV-2) virus, which can cause severe acute respiratory syndrome through the droplet, has caused the global Coronavirus 19 (COVID-19) pandemic. COVID-19 infection can be asymptomatic or lead to serious illness and even death. This virus causes a hypersensitive immune reaction and varying degrees of widespread inflammation through cytokines in various organs of the body, mainly the lungs.

Cytokine-mediated widespread inflammation caused by the virus may also affect the parathyroid glands, causing their functions to deteriorate. Thus, it may cause changes in parathyroid hormone secretion.

The researchers evaluated the results of serum parathyroid hormone, calcium, phosphorus, alkaline phosphatase tests in patients who were symptomatic and hospitalized with COVID-19 infection. Participants also evaluated the relationship of parathormone with white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone levels of patients with COVID-19 infection with the parathyroid hormone levels of healthy individuals without COVID-19 infection and parathyroid disease. So the investigators looked for differences in parathyroid hormone levels between both groups. Researchers did not include patients in the intensive care unit and patients with known parathyroid disease.

Eligibility Criteria:
Inclusion Criteria:

* To accept research.
* Being over the age of 18.
* COVID 19 test results to be positive.
* Not taking parathyroid disease medication before.
* Receiving inpatient treatment in the COVID service in the hospital.

Exclusion Criteria:

* Not accepting research.
* Be under the age of 18.
* Negative COVID 19 test results for patients.
* COVID patients treated as outpatient.
* Parathyroid disease in the healthy control group.
The CCUS Based Characteristic of Hemodynamic and Lung Pathology in Early Stage of Shock in ICU: The Epidemic and Prognostic Value

Shock is a common condition in critical care unit (ICU). It is extremely important that the patient accepts early goal-directed therapy (EGDT) treatment in the early stage of shock. However, several studies failed to demonstrate that the well used variables such as CVP and others could direct to a better treatment. In recent years, critical care ultrasound (CCUS) has been respected as a reliable noninvasive tool and widely used in ICU practice. With CCUS the investigators can accurately acquired the detailed information of the characteristic of the hemodynamics and lung pathology (the systole and diastole function, volume status, valve insufficiency, lung, edema, consolidation, and pleural effusion, etc.). To the investigators knowledge, there is no study investigating the epidemic of such ultrasonic variables and its value to predict to outcome. The aim of this study is to investigate the epidemic and the prognostic value of CCUS Based Characteristic of Hemodynamic and Lung pathology in Early Stage of Shock in patients admitted in ICU.

Adult patients who admitted to the intensive care unit of West China hospital of sichuan university with shock from April 2016 to April 2017 enrolled.

Eligibility Criteria:
Inclusion Criteria:

1. SBP\<90 mm Hg or MAP \<70 mm Hg or SBP decrease \>40mmHg or need vasoactive drugs;
2. Skin that is cold and clammy, capillary refill time \>4.5s, urine output of \<0.5ml/Kg.hr and lactate\>2mmol/L;
3. SHOCK presented within 6 hr.

Exclusion Criteria:

1. \<18 years old;
2. Pregnancy;
3. Patient or family member refuse to be enrolled.
Prevention of POV After Paediatric Tonsillectomy

Tonsillectomy is one of the most frequently performed surgical procedures in children. It remains associated with a high morbidity related to postoperative vomiting (POV), pain, risk of bleeding, and dehydration due to impaired oral intake. Current medications for POV have limited efficacy and may even be associated with potential side-effects. Non-pharmacological techniques such as acupuncture has been investigated as alternatives to antiemetics and as additional treatment modalities for POV.

Postoperative vomiting (POV) is one of the most common complication in children undergoing tonsillectomy. Its incidence is between 62% and 73% when no prophylactic antiemetic is given. Because of Limited efficacy and side effects with antiemetics, many alternative treatment had been used. Acupuncture is simple, inexpensive, and noninvasive with minimal side effects. The objective of this study is to compare two prophylactic antiemetic treatments :

* Dexamethasone (0.15 mg/kg) immediately after induction of anaesthesia
* Acupuncture treatment (immediately after induction of anaesthesia and for approximately 20 minutes)

Eligibility Criteria:
Inclusion Criteria:

* children aged 2-8 y.
* children ASA 1-2
* tonsillectomy with or without adenoidectomy

Exclusion Criteria:

* American Society of Anesthesiologists grade greater than or equal to III (patient with severe systemic disease)
* intravenous induction
* contraindication to steroids
* Rash or local infection over an acupuncture point
* administration of steroids in the 24 hours before the surgery
* Use of medication with antiemetic effect within the 24 hours before surgery
* Gastric or intestinal diseases
* refusal of parents
A Study of LY317615 in Patients With Brain Tumors

1. The safety of LY317615 and any side effects that might be associated with the drug.
2. Whether LY317615, can help patients with brain tumors.


Eligibility Criteria:
Inclusion Criteria:

* You must be at least 18 years old
* You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
* You must be able to swallow the LY317615 tablets

Exclusion Criteria:

* You are a woman who is pregnant or breastfeeding
* In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease
The Prevalence and Implications of Obstructive Sleep Apnea in the Population of a Wound Center

This study is looking at the prevalence of sleep apnea in a wound center population. It uses both screening surveys and take home devices. Some measures of wound healing ability are being looked at as well.

Patients with chronic non-healing wounds often have major co-morbidities such as diabetes and cardiovascular diseases \[1\]. Obstructive Sleep Apnea (OSA) is present in up to 24% of middle-aged adults \[2\], and is far more prevalent in patients with existing cardiovascular disease \[3\]. Patients with OSA are at increased risk of developing diabetes l \[4\]. OSA is an established cause of hypertension\[5\], and has an estimated prevalence of 40% in all patients with hypertension \[6-8\]. Similarly a strong association exists between OSA, coronary artery disease \[6, 7\] and stroke \[8\]. OSA may be present in over 50% of patients with heart failure \[9\]. Patients with chronic non-healing wounds stand to benefit from identification and treatment of severe co-morbidities such as OSA. Such identification and treatment of OSA will impact the survival of these patients \[10, 11\], and may also contribute to improved morbidity via impacting wound healing.

Several unexplored links exist between OSA and wound healing. OSA is a disorder of intermittent hypoxia and is associated with increased oxidative stress \[12\]. Humans with OSA and animal models of intermittent hypoxia developed impaired vascular function and nitric oxide deficiency. Patients with OSA have impaired endothelial function even in the absence of clinically apparent cardiovascular disease \[13-15\]. Increased sympathetic activity and episodic pressor response are well documented in OSA. Patients with OSA have increased vascular tone and baseline vasoconstriction \[16\]. Impaired vascular reactivity to hypoxia was also demonstrated in animal models exposed to 2 weeks of intermittent hypoxia\[17\]. Therefore, in patients with chronic non-healing wounds, OSA is likely to further complicate the healing process.

OSA as a disorder of oxidative stress and vascular impairment is most likely an important co-morbidity in patients with non-healing wounds. Other potential mechanisms of interaction are the inflammatory response associated with OSA

Eligibility Criteria:
Inclusion Criteria:

* OSU Wound Clinic Patient

Exclusion Criteria:

* Unable to complete survey
* Under 18yrs old
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

This is an open-label study designed to evaluate the long-term safety and efficacy of evinacumab, a fully human ANGPTL3 antibody, in patients with homozygous familial hypercholesterolemia (HoFH), in a real-life setting in Canada.

Eligible patients for this study are male and female adult patients with HoFH. Evinacumab will be added on top of the patient's background lipid-modifying therapy (LMT), including statins, ezetimibe, PCSK9 inhibitors, lomitapide or other lipid lowering therapies. This study will be conducted using an hybrid (on-site, foldable sites) approach. Patients will enter the current study, in an open-label treatment period, following their screening. This study will continue until reimbursement of evinacumab in Canada or for a maximum of 24 months. The end of study (EoS) visit will be scheduled 4 weeks after the last dose has been injected and will be followed by a 52-week follow-up.


Eligibility Criteria:
Inclusion Criteria:

* HoFH patients having been previously or being currently treated with evinacumab or clinical diagnosis of HoFH requiring additional lipid lowering therapy.

Exclusion Criteria:

* Any new condition or worsening of an existing condition, which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study;
* Pregnant or breastfeeding women;
* Women of childbearing potential who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 24 weeks after the last dose of study drug.
The Effect of Latent Tuberculosis Infection on the Pregnancy Outcome of IVF-ET

This study evaluate the effect of latent infection of tuberculosis on the pregnancy outcome of IVF-ET in infertile patients with radiographic lesions suggesting old healed tuberculosis

China is one of the countries with high burden of tuberculosis (TB) defined by WHO. IVF-ET is an effective method to treat infertility. Chest X-ray is a routine examination before IVF-ET, which can exclude active tuberculosis. However, for patients with chest X-ray showing old healed tuberculosis, the relationship between latent tuberculosis infection (LTBI) and pregnancy outcomes is unknown. In this study, a prospective cohort study was carried out in infertile women who were planning to receive IVF-ET. IGRA were tested in patients with old tuberculosis in chest X-ray. A cohort of IGRA positive and IGRA negative was constructed. The pregnancy outcomes were followed up prospectively and the relationship between latent infection of tuberculosis and pregnancy outcomes was analyzed. The primary outcome was clinical pregnancy rate, miscarriage rate and live birth rate. Secondary outcomes were tuberculosis reactivation during pregnancy period and in 3 months after delivery.

Eligibility Criteria:
Inclusion Criteria:

* The patients who referred to the reproductive center for IVF-ET
* Chest radiography showed old healed tuberculosis

Exclusion Criteria:

* active tuberculosis
3D Analysis of Peri-implant Soft Tissue with Two Different Connection Types

Objectives: assessment of dimensional soft tissues change after single tooth gap implantation with a closed healing approach and using conical and butt-joint implant-abutment connection type.

Material and Methods: forty patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, immediately, two, 7 and 14 days post-op, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months after delivery. The intraoral scans were matched in the metrology software (Geomagic Control X). The mean maximum and mean average differences in mm were gathered to assess the soft tissues change. Various anamnesis parameters have been taken into account.


Eligibility Criteria:
Inclusion Criteria:

* Presence of a single tooth gap, completion of conservative and periodontal treatments, diagnostic preoperative models, and a recent panoramic radiograph not older than 6 months.

Exclusion Criteria:

* Abnormal jaw anatomy, insufficient bone volume, bone conditions (e.g., cysts, tumors), oral mucosa abnormalities (e.g., lesions, diseases), untreated periodontal disease, acute inflammation, pregnancy, temporary medication contraindications, psychological issues (e.g., substance abuse), poor compliance, and general medical contraindications.
EEG Motor Movement and Imagery Dataset for Stroke

The investigators collect and analyze the alpha and beta wave of EEG activity at the motor cortices of the participants, When the motor task is being performed. The Brodmann area 10-20 method and portable EEG equipment was used in the single-center study.

To understand the motor mechanism of stroke patients with motor dysfunction, an EEG motor movement and imagery dataset for Stroke will be created. 120 subjects will be enrolled in the single-center study. The investigators collect and analyze the EEG activity at the motor cortices of the participants, When the motor movement or imagery task is being performed. The alpha and beta wave of EEGs were recorded from 32 electrodes as per the international 10-20 system with portable EEG equipment.

Eligibility Criteria:
Inclusion Criteria:

1. The diagnosis of cerebral infarction conforms to the diagnostic criteria of Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018, and the diagnosis of intracerebral hemorrhage conforms to the diagnostic criteria of Chinese guidelines for the diagnosis and treatment of intracerebral hemorrhage 2019.
2. First onset.
3. Age ≥ 18 years old.
4. Motor dysfunction of upper and / or lower limbs: muscle strength decreased by 0 to 5-grade and / or ataxia.
5. Informed consent has been signed.

Exclusion Criteria:

1. Vital signs are unstable.
2. Serious circulatory system, respiratory system, motor system and other diseases, such as atrial fibrillation, heart failure, pulmonary infection, severe liver and kidney insufficiency, lower extremity venous thrombosis and other serious diseases.
3. Functional impairment of upper or lower limbs caused by other diseases of nervous system or other reasons, such as fracture, deformity, etc.
4. Unable to cooperate to complete the examination, such as mental disorder, cognitive impairment, visual impairment, sitting balance disorder, etc
5. Other reasons: alcoholism; Skull defect; Head skin defect, etc.
Immediate Effects of Bowen Technique Versus Dynamic Soft Tissue Mobilization on Hamstrings Tightness in Chronic Non-specific Low Back Pain.

Low back pain (LBP) is leading cause of disability and its burden is growing worldwide with an increasing and ageing of population. Poor flexibility or tightness of hamstring muscle has been associated with low back pain. It is a prominent cause of activity limitations and work absenteeism throughout world. Hence this study was designed to find out superior form of effective technique on active knee extension and experience of pain and disability in chronic nonspecific low back pain.

Low back pain (LBP) is leading cause of disability and it is most leading cause of work absenteeism throughout world. Poor flexibility or tightness of hamstring muscle has been associated with low back pain. Hence this study was designed to find out superior form of effective technique on hamstrings tightness and experience of pain and disability in chronic nonspecific low back pain. This study will also assist to set the foundation for further more studies designing magnificent protocols of treatment for affected population.

Eligibility Criteria:
Inclusion Criteria:

* The patients aged 18-45 years will be included in the study.
* Patients with chronic low back pain (more than 3 months) will be included.
* Both genders.
* 20 to 40 degrees active knee extension loss with hip in 90 degree flexion
* Pain Intensity (moderate to severe) NPRS (4-6 intensity)

Exclusion Criteria:

* Individuals who were receiving treatment for their pain with another(medical treatment) at the same time
* Patients who had undergone vertebral column surgery (less than three months before the time of this study).
* Patients with the infection, neoplasms, metastasis, rheumatoid arthritis, fractures or inflammatory processes were excluded.
* Dislocations of lower limb
* Hypermobility of lower limb joint
* Hamstrings injuries
* Nerve lesions of lower limb
Oral Cancer Screening in Mumbai, India by Primary Health Care Workers

A feasibility study to compare the test characteristics of three different oral cancer screening techniques performed by trained primary health care workers:1)Unaided Visual Inspection, 2)VelScope Assisted Examination, and 3) Examination after application of Toluidine Blue dye.

Oral cancer is the most common cancer among men in India mainly due to the habit of using smokeless tobacco. Pre-cancerous lesions like leukoplakia, melanoplakia, erythroplakia,oral submucous fibrosis and indolent ulcers can be easily detected by periodic examination of the oral cavity of the at-risk populations. Several methods of oral cancer screening have been tried over the past three-four decades with varying success. This study investigates the feasibility of application and compares the test characteristics of three oral cancer screening techniques: Unaided Visual Inspection, VelScope assisted examination and examination after application of Toluidine blue dye by primary health care workers among tobacco users attending a cancer early detection clinic, in Mumbai, India.

Eligibility Criteria:
Inclusion Criteria:

* The study participants will be apparently healthy males with tobacco habit ( present tobacco users and those who have quit within past six months),
* above 18 years of age,
* attending Preventive Oncology clinic.

Exclusion Criteria:

* Participants with frank oral cancers will not be recruited in the study.
D-serine for Posttraumatic Stress Disorder Treatment

The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance\& depressive symptomatology that may be mediated by NMDA receptor function deficits.

Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (\~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.


Eligibility Criteria:
Inclusion Criteria:

• Chronic PTSD (DSM-IV diagnosis)

Exclusion Criteria:

* Other psychiatric diagnosis
* Substance abuse
* Unstable medical condition